Herantis Pharma Plc, Press Release, 7 December 2022 at 09:00 A.M. EEST
Herantis Pharma Plc (“Herantis”), developing disease modifying therapies for Parkinson’s disease, today announced that CEO, Antti Vuolanto will participate and give a company presentation at:
Inderes Life Science evening
Date: December 13, 2022
Location: Helsinki, Finland
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit www.herantis.com